Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with vibegron may increase the plasma concentrations and effects of drugs that are substrates of the P-glycoprotein (P-gp) efflux transporter. The exact mechanism for this interaction has not been established. When a single dose of vibegron (100 mg) was administered to healthy volunteers, the peak plasma concentration (Cmax) and systemic exposure (AUC) of the P-gp substrate digoxin increased by 21% and 11%, respectively. The risk of adverse reactions related to these substrates may be increased.

MANAGEMENT: Caution is advised if vibegron is coadministered with substrates of P-gp, particularly sensitive substrates or those with a narrow therapeutic range. The prescribing information for concomitant medications should be consulted to assess the benefits versus risks of coadministration and for any dosage adjustments that may be required.